Research programme: small molecule protein inhibitors - Cypralis
Latest Information Update: 28 Aug 2020
Price :
$50 *
At a glance
- Originator Cypralis Limited
- Class Small molecules
- Mechanism of Action Cyclophilin inhibitors; Peptidylprolyl isomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammation; Wounds
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for research development in Inflammation in United Kingdom
- 28 Aug 2020 No recent reports of development identified for research development in Wounds in United Kingdom
- 16 Jan 2020 Cypralis has patent protection for small molecules that indicate potent inhibition of cyclophilins in the UK (Cypralis website, January 2020)